Samsung Bioepis, Teva expand strategic partnership to advance up to six potential biosimilar candidates
TEVA•Samsung Bioepis and Teva expanded their strategic partnership to advance up to six potential biosimilar candidates, with the collaboration covering the United States, Europe and Canada.
1. Partnership details
Samsung Bioepis and Teva will be co-responsible for development and manufacturing, while Teva will handle commercialization in the United States, Europe and Canada. The partnership includes an option to expand to other territories.
